Biotech and Money are pleased to announce the release of the latest Drugs & Dealers Magazine. The March issue is the second of 6 bi-monthly publications in 2016 aimed at providing insight, foresight and hindsight to life science executives involved in funding, investment, partnering and deal making.

DOWNLOAD the PDF Magazine here

Here’s what you can expect to read from the digitally interactive March issue:

• Diurnal Exclusive Interview: We talk to CEO Martin Whitaker on what the future holds for the endocrinology company after its successful £30m AIM listing from December 2015. The last UK Biotech to successfully tap public markets in 2015.

• FEATURE: Mann Bioinvest Investor Exclusive Interview: We talk to Andy Smith, CIO of Mann Bioinvest to understand how important healthcare and life sciences are to him what drives his decision to invest in certain companies over others.

• MISSION Therapeutics Exclusive Interview: We find time with Anker Lundemose, CEO to talk through the company’s successful £60m private fund raise, the key success factors and why the public market route was not the obvious choice for the company.

• FEATURE: APOLLO Therapeutics Investment Committee Exclusive Interview: We chat to Dr Ian Tomlinson, Chairman of the newly formed consortium fund to discuss its aims and objectives of the £40m collaboration and the uniqueness of the models and its members.

• Shield Therapeutics Exclusive Interview: Hot on the heels of their 2016, £32.5m AIM listing, we interview Carl Sterritt, CEO of the first UK Biotech to get a listing away on AIM in 2016. We talk strategy, business models and the key to tapping public markets in a downturn market.

• JAG Shaw Baker Exclusive Interview: We hear from the Co-Founder and Partner, James Shaw and get a sense for industry and market direction from a law firm central to the EU tech and venture capital eco-system.

• Motif Bio Exclusive Interview: Almost a year to the day of Motif Bio’s AIM listing, we talk to CEO Graham Lumsden on what life is like as a publicly listed company, what have been the lessons of the first 12 months and what will we can expect to see in 2016.

• Medicxi Ventures Exclusive Interview: Co-Founder and Partner Francesco de Rubertis shares his views on the future of the newly launched GSK and J&J backed £210M fund, formed out of Index Ventures and provides market insight on future market shifts.

• FEATURE: Birmingham Research Park and BioHub: James Wilkie, CEO of Birmingham Research Park shines a spotlight on the Birmingham Life Science eco-system and explains why companies and investors alike should be looking beyond the ‘Golden Triangle’.

• Abingdon Health Exclusive Interview: CEO Chris Yates, a prominent tenant at the Birmingham BioHub outlines what attracted his company to the area and why he expects the community to go from strength to strength.

• Verona Pharma Exclusive Interview: Jan-Anders Karlsson, CEO unwraps the company’s core focus around the $1bn respiratory market and outlines their plans for their lead candidate and broader future pipeline growth.

DOWNLOAD the PDF Magazine here